Oncoplastic breast-conserving surgery with BioZorb® technology
https://www.facingourrisk.org/XRAY/oncoplastic-breast-conserving-surgery
Full article: http://www.columbian.com/news/2018/jan/22/breast-cancer-surgeon-diagnosed-with-breast-cancer-advocates-oncoplastic-surgery/
The January 22, 2018 issue of The Columbian included an interview with Dr. Anne Peled in its online report, “Breast cancer surgeon diagnosed with breast cancer advocates oncoplastic surgery.” Dr. Peled is a 37-year-old breast cancer surgeon and plastic surgeon from California who was recently diagnosed with breast cancer. She underwent oncoplastic lumpectomy—a single surgery that removes the tumor and rearranges the remaining tissue to eliminate any resulting breast deformity. Peled’s procedure included a relatively new technology that she uses for her own patients: an implanted BioZorb® marker, a small device that improves precise targeting of radiation therapy and cosmetic outcome. (2/8/18)
Update 08/02/2024
On May 22, 2024, the FDA issued a safety notification on BioZorb Markers. This is due to reports of people having adverse reactions to BioZorb Markers placed in breast tissue.
These included infection, fluid buildup, movement of the marker, either through the skin or to another location in the breast, discomfort due to feeling the device in the breast and rash. This safety alert does not call for removal of BioZorb Markers. People should report any reactions to BioZorb to their doctor and the FDA. You can read more about this safety notification here.
Questions To Ask Your Health Care Provider
- Is a lumpectomy or mastectomy more effective for me?
- Do you provide oncoplastic lumpectomy? If not, how can I find a surgeon who does?
- Will I need radiation therapy after my lumpectomy?
- Can I benefit from a BioZorb implant?
Open Clinical Trials
The following studies are related to mastectomy and breast reconstruction.
- NCT05720039: Nipple-Sparing Mastectomy With Immediate Implant-Based Reconstruction for Women With Early-Stage Breast Cancer. This study will compare robotic-assisted nipple-sparing mastectomy (NSM) to standard surgery NSM for women with early-stage breast cancer.
- NCT02918474: Decision-Making Tool in Supporting Decision-Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer. This trial studies the acceptability and usefulness of a tool that supports decision-making for contralateral prophylactic mastectomy in patients with newly diagnosed breast cancer.
- NCT04533373: Sensory Restoration After DIEP Flap Neurotization. The goal of this study is to look at whether nerve graft works to improve sensation in the breast after mastectomy with DIEP flap reconstruction.
-
NCT05020574: Microbiome and Association With Implant Infections. This study is looking at whether people with high amounts of certain types of bacteria are more likely to develop tissue expander-related infections than those with lower amounts of bacteria.
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.